NASDAQ:SUPN

Supernus Pharmaceuticals Stock Predictions

Healthcare > Drug Manufacturers - Specialty & Generic

Buy SUPN

*Your capital is at risk

$44.48

+0 (+0%)

At Close: Jun 23, 2026

Currently predicting for Wed, 24 Jun 2026

SUPN Live board

Community Bull/Bear

Target Next close

Join the SUPN prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

SUPN Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For SUPN

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

SUPN Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT SUPERNUS PHARMACEUTICALS

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy tr...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.98	18.12%	Jun 12
DHI $146.71	6.29%	Jun 10
PHM $118.49	6.02%	Jun 10
EAT $140.46	17.09%	Jun 05
E ETD $20.67	3.19%	Jun 05

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by